(Q80698928)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17662376%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

editorial

0 references

title

Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17662376%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

main subject

phase III clinical trial

1 reference

1 reference

Maurie Markman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17662376%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

1 August 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17662376%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17662376%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17662376%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17662376%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

279-281

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17662376%20AND%20SRC:MED&resulttype=core&format=json

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.06.005

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.06.005

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.06.005

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.06.005

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.06.005

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.06.005

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.06.005

Why study third-, fourth-, fifth-, ...line chemotherapy of ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.06.005

Viewing ovarian cancer as a "chronic disease": what exactly does this mean?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.06.005

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.06.005

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.06.005

10.1016/J.YGYNO.2007.06.005

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17662376%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference